Trial Profile

Phase III Study of AJM300 in Patients With Active Ulcerative Colitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carotegrast (Primary)
Indications Ulcerative colitis
Focus Registrational; Therapeutic Use
Sponsors EA Pharma; Kissei Pharmaceutical

Most Recent Events

20 Jul 2023 Status changed from active, no longer recruiting to completed.
31 Mar 2022 Results presented in an EA Pharma Media Release.
31 Mar 2022 According to an EA Pharma media release, data published in The Lancet Gastroenterology & Hepatology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com